Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

• Type of Material: Article
• Authors: Jacob M Sands, Dana-Farber Cancer Institute; Sumithra J Mandrekar, Mayo Clinic, Rochester; David Kozono, Dana-Farber Cancer Institute; Geoffrey R Oxnard, Dana-Farber Cancer Institute; Shauna L Hillman, Mayo Clinic, Rochester; Dennis A Wigle, Mayo Clinic, Rochester; Ramaswamy Govindan, Washington University in St. Louis; Jennifer Carlisle, Emory University; Jhanelle Gray, Washington University in St. Louis; Jospeh K Salama, Duke University; Luis Raez, Florida International University; Apar Ganti, Duke University; Nathan Foster, Mayo Clinic, Rochester; Shakun Malik, Florida International University; Jeffrey Bradley, Emory University; Karen Kelly, University of California Davis; Suresh Ramalingam, Emory University; Thomas E Stinchcombe, Duke University
• Language: English
• Date: 2021-04-21
• Publisher: FUTURE MEDICINE LTD
• Publication Version: Final Published Version
• Copyright Statement: © 2021 Alliance for Clinical Trials in Oncology
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.2217/imt-2021-0019
• Title of Journal or Parent Work: IMMUNOTHERAPY
• Volume: 13
• Issue: 9
• Start Page: 727
• End Page: 734
• Grant/Funding Information: Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), UG1CA233180, UG1CA233253, UG1CA233247, UG1CA233339, and UG1CA232760.
• Keywords: pembrolizumab; adjuvant chemotherapy; Science & Technology; Immunology; lung squamous cell carcinoma; Life Sciences & Biomedicine; NSCLC; lung adenocarcinoma
• Research Categories: Health Sciences, Oncology; Health Sciences, Medicine and Surgery

Abstract

Non-small-cell lung cancer (NSCLC) causes significant mortality each year. After successful resection of disease stage IB (>4 cm) to IIIA (per AJCC 7), adjuvant platinum-based chemotherapy improves median overall survival and is the standard of care, but many patients still experience recurrence of disease. An adjuvant regimen with greater efficacy could substantially improve outcomes. Pembrolizumab, a programmed cell death-1 inhibitor, has become an important option in the treatment of metastatic NSCLC. ALCHEMIST is a clinical trial platform of the National Cancer Institute that includes biomarker analysis for resected NSCLC and supports therapeutic trials including A081801 (ACCIO), a three-arm study that will evaluate both concurrent chemotherapy plus pembrolizumab and sequential chemotherapy followed by pembrolizumab to standard of care adjuvant platinum-based chemotherapy. Clinical trial registration: NCT04267848 (ClinicalTrials.gov.